Google has also established a joint venture with a pharmaceutical company. This is how much money will be spent on life sciences.

Recently, Verily, a life sciences company owned by Google, and the French pharmaceutical company Sanofi have jointly established a new company, Onduo, to jointly develop diabetes products. Among them, Sanofi invested 248 million U.S. dollars, accounting for 50% of the shares.

In fact, as early as last year, Verily cooperated with Sanofi in the diabetes detection and treatment project. The two parties can play a complementary role to a certain extent: Verily has a certain amount of accumulation in microelectronics, analysis, and software development, and Sanofi has deep clinical knowledge and experience. Both parties declared: â€œ Onduo will initially focus on the type 2 diabetes community and we will look for solutions to help patients make decisions â€“ decisions related to daily health, such as improving medical management, changing habits, and strengthening goals.â€

In recent days, Verily has frequently conducted strategic cooperation with traditional pharmaceutical factories, smart equipment companies, and biomedical institutions. Last month, Verily established Galvani Bioelectronics with GlaxoSmithKline , the UK's largest pharmaceutical company. It is reported that both sides are committed to the development of micro-implantable devices to intervene in synaptic signals to regulate irregular or disorganized pulses caused by some diseases.

Of course, Verily faces many problems behind the frantic expansion of territories. Previously it developed a smart eyewear that integrates tens of thousands of transistors to help diabetics monitor their blood glucose levels by analyzing glucose levels in the wearer's tears. However, some insiders broke the news that the product is currently unable to accurately monitor blood sugar levels, and it is very straightforward to describe it as a PPT product. At the same time, companies that research and develop similar products have all ended up failing for the same reason. From the medical community's feedback, tears do not accurately reflect the level of blood glucose in the body. Lei Feng Network (search "Lei Feng Net" public concern) has also thoroughly started Verily's project, in general, its products are still in the early stages of R & D, far from reaching the popular stage.

Although extremely ambitious and surreal, Verily looks very picturesque and carries many people's hopes. But after all, biomedical care is an extremely difficult and important direction that involves people's lives. From the idea to landing to commercialization, Verily seems to have gone very hard.